Board of Directors

Portrait

Dr. Hirth has served as Chairman of our board of directors since September 2016. Dr. Hirth founded Plexxikon, Inc., a pharmaceutical company, in 2000 and served as its Chief Executive Officer until May 2013. Dr. Hirth currently serves on the board of directors of Aligos Therapeutics, a biopharmaceutical company, and Vaxcyte, Inc., a biotechnology company, as well as the boards of several private life sciences companies. Dr. Hirth received a Ph.D. in Molecular Genetics from Heidelberg University, Germany, and completed his post-doctoral work at the University of California, San Diego.

Portrait

Dr. Belawat has served as a member of our board of directors since January 2021. Dr. Belawat has over 13 years of experience in venture and private equity investing in the healthcare space and has served as an Investment Advisor at HBM Partners AG since February 2007. Dr. Belawat actively manages investments in the biopharmaceutical industry, especially drug development in oncology, neurology, sepsis and fibrosis in geographies like the U.S., Europe and selected emerging markets like China and India. Dr. Belawat received a Ph.D. in molecular biology and genetics from the University of Zurich, and completed her post-doctorate work at the Hong Kong University of Science and Technology. Dr. Belawat is a board member of BioAtla, Inc., BioNeurelis Inc., iTeos Therapeutics, Inc. and Adrenomed AG.

Portrait

Christian joined Lundbeckfonden in 2012 and is the managing partner of Lundbeckfonden BioCapital, the evergreen biotech investment unit of Lundbeckfonden and part of the leadership team of Lundbeckfonden. Christian applies more than 20 years of experience across drug development, biotech and venture capital. He is the chairperson of the board of directors of SNIPR Biome and Cytoki Pharma and member of the board of directors of IO Biotech, NMD Pharma, Afyx Therapeutics. He was a co-founder, VP and CEO of 7TM Pharma. Christian holds a PhD in Pharmacology from the University of Copenhagen, Denmark.

Portrait

Mr. Nielsen has served as a member our board of directors since January 2021. Since August 2017, Mr. Nielsen has served as a Managing Director at Vivo Capital LLC, a healthcare focused investment firm and was recently promoted as a Managing Partner. Prior to March 2017, Mr. Nielsen worked within the Novo Holdings A/S organization and its venture activities since 2001 in several roles, most recently being employed as a Senior Partner based in Copenhagen, Denmark. Mr. Nielsen is currently a member of the board of directors of Aligos Therapeutics, Inc., Reata Pharmaceuticals, Inc., Harmony Biosciences, ALX Oncology Holdings Inc. and Instil Bio, Inc., all of which are publicly traded companies, and a number of private companies. Mr. Nielsen, in the past, has served on the boards of directors of Akebia Therapeutics, Inc., Crinetics Pharmaceuticals, Inc., Merus, N.V. and Apollo Endosurgery, Inc., each of which is publicly traded. Mr. Nielsen received a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Masters in Management of Technology and Economics from the Center for Technology, Economics and Management, Technical University of Denmark.

Portrait

Ms. Glaub has served on our board of directors since May 2018. Ms. Glaub is co-founder and executive chair for the board of CuraSen Therapeutics, Inc., a biotechnology company, a position she has held since October 2018. From November 2013 until the acquisition of the company by Merck in July 2016, Ms. Glaub served as a director on the board of Afferent Pharmaceuticals. She also served as the Chief Executive Officer of Afferent Pharmaceuticals from August 2014 to October 2016. Previously, she served as president of Plexxikon, Inc. from November 2001 to May 2013. Prior to Plexxikon, Ms. Glaub held positions as senior vice president and chief financial officer of Cell Genesys, Inc., a public biotechnology company, treasurer of Genentech, Inc, a public biotechnology company, and various finance and treasury roles with Intel Corporation, a public technology company. She also serves as a director on the board of Escient Pharmaceuticals, Inc., a private biotechnology company. She previously served on the boards of Codexis, Inc., a publicly traded protein engineering and therapeutics company, and Aligos Pharmaceuticals, Inc., a publicly traded biotechnology company. Ms. Glaub also serves as a member of the investment advisory board to the Bailard Healthcare Fund. Ms. Glaub received a B.A. from the University of California, Berkeley, and an M.B.A. from Northwestern University Kellogg School of Management.

Portrait

Mr. Smith has served on our board of directors since March 2022. From November 2018 until the acquisition of the company by Amgen in April 2021, Mr. Smith served as Executive Vice President and Chief Financial Officer at Five Prime Therapeutics, a publicly traded company focused on discovering and developing novel immuno-oncology protein therapeutics. Previously, Mr. Smith served as Chief Operating Officer of IntegenX, Inc. from May 2012 to March 2018 and before that as Chief Financial Officer of Thoratec, Chiron and Anergen, Inc from December 2006 to July 2011. He has also held finance positions with Genentech, Inc., Syntex Corporation and IBM. Mr. Smith is currently the Chair of the Audit and Strategy Committees of Codexis, Inc., the Chair of the Audit Committee of Neurelis, Inc., and a Director of Acepodia, Inc. Mr. Smith holds a B.A. in Economics and History from Willamette University and an M.B.A. in Finance from Golden Gate University.

Portrait

Dr. Zocca has served as our founder and Chief Executive Officer since January 2015. Dr. Zocca was also the founder and Chief Executive Officer of OncoNOx ApS, a pharmaceutical company, from July 2011 until May 2019. Prior to founding the Company, she was the Chief Executive Officer at LevOss ApS, a biotechnology company, from January 2012 until January 2017. Dr. Zocca also led DanDrit Biotech A/S, a biotechnology company, as its Chief Executive Officer from July 2007 until December 2010. Dr. Zocca currently serves on the board of directors for Dansk Biotek, a Danish biotechnology trade organization, and Valo Therapeutics Ltd., a biotechnology company. Dr. Zocca received her M.Sc in Biochemistry as well as Ph.D. in Medicine from the University of Copenhagen and NIH, NCI, MD, US.

Science Board Advisors

Portrait

Dr. Dhingra is a medical oncologist and a physician-scientist with a proven track record in academic research, patient care, and drug development. He served as Vice President, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development at Hoffmann-La Roche (“Roche”), during which he led numerous drug approvals, including Herceptin®, Tarceva®, and Avastin®. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. Dr. Dhingra has served as a faculty member at The University of Texas M.D. Anderson Cancer Center, Indiana University School of Medicine, and Memorial Sloan Kettering Cancer Center. Dr. Dhingra is currently a member of the Boards of Directors of LAVA Therapeutics, Black Diamond Therapeutics, Inc., Replimune, Inc., Autolus Therapeutics plc, and Median Technologies, and he has previously served on the boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, Epitherapeutics, Advanced Accelerator Applications, Exosome Diagnostics, and, Five Prime Therapeutics. He is a member of the NCI Experimental Therapeutics Panel. Dr. Dhingra founded KAPital Consulting, LLC in 2008, a company dedicated to helping biotechnology, pharmaceutical, and diagnostic companies realize the clinical and commercial advances in oncology. Dr. Dhingra obtained his M.B.B.S. degree from the All India Institute of Medical Sciences in New Delhi, India. He completed his residency in internal medicine at Lincoln Medical and Mental Health Center, New York Medical College and completed his fellowship in hematology and oncology at Emory University School of Medicine.

Portrait

Professor and Director of CCIT (Center for Cancer Immune Therapy at Herlev University Hospital. Mads Hald Andersen has received several honors for his scientific work and is the author of more than 130 papers. MHA has founded and co-founded several spin out companies with a successful sale of Survac in 2006.

Portrait

Professor and Director of CCIT (Center for Cancer Immune Therapy) at Herlev University Hospital. IMS has extensive experience in clinical translation of immune therapies and is an advisor for several large pharma companies. Currently running a phase III trial.

Portrait

Alexander Eggermont, MD, PhD, is currently Professor of Immunotherapy at the University Medical Center Utrecht in the Netherlands, Scientific Director of the Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands and Board Member of the Comprehensive Cancer Center Munich between the Technical University Munich and the Ludwig Maximiliaan University, Munich, Germany.

He is the past Directeur Général of the Gustave Roussy Cancer Institute (2010-2019) and Professeur Oncologie «Classe Exceptionelle», at the Université Paris-Saclay (2012-2020). He was head of Department of Oncological Surgery at the Erasmus University of Rotterdam, Netherlands 2003-2017. He also holds the Joseph Maisin Honorary Chair of Oncological Surgery at the Louvain Catholic University (Belgium). He is a Melanoma, Soft tissue sarcoma and Immunotherapy specialist and Fellow of the NIH-NCI Surgery Branch (Chief Steve Rosenberg). During his career, he was o.a. President of the the EORTC (European Organization for Research and Treatment of Cancer) from 2003 to 2006 and President of ECCO (European CanCer Organization) from 2008 to 2010, and President of the of the European Academy of Cancer Sciences (2011-2019).